GW Pharmaceuticals (GW) is a British biopharmaceuticals company that is the largest assignee in the sector. GW is focused on developing and marketing therapeutics based on plant-derived cannabinoid compounds. GW saw early success with Epidolex, the first cannabis plant-derived medicine approved by the FDA, which is used to treat patients with rare epilepsy diseases (Dravet syndrome and Lennox-Gastaut syndrome). GW also has developed Sativex, which is used to treat patients with multiple sclerosis. GW is primarily focused on neurological conditions, including conditions with both orphan and non-orphan status.